<DOC>
	<DOCNO>NCT02670018</DOCNO>
	<brief_summary>A Randomized , Open-label , Single-dose , Two-way Crossover Clinical Trial Investigate Pharmacokinetics Safety/Tolerability Combination Gemigliptin/Metformin HCl Sustained Release 50/2000 mg ( 25/1000 mg x 2 tablet ) Comparison Each Component Gemigliptin 50 mg Metformin HCl Extended Release 2000 mg ( 1000 mg x 2 tablet ) Administered Healthy Male Volunteers .</brief_summary>
	<brief_title>BE Study Combinations Gemigliptin 50mg Metformin HCl Extended Release 2000mg Comparison Each Component Administered Alone</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<criteria>Age 19 45 , healthy male subject ( screen ) Body weight 55kg 90kg , BMI 18.0 27.0 FPG 70125mg/dL glucose level ( screen ) Subject totally understand progress clinical trial , make decision free , signed consent form follow progress . Subject past present history disease follow . ( liver include hepatitis virus carrier , kidney , Neurology , immunology , pulmonary , endocrine , hematooncology , cardiology , mental disorder . ) Subject GI tract disease ( ulcer , acute chronic pancreatitis ) surgery . ( appendectomy , hernioplasty include ) Subject drug hypersensitivity reaction . ( Aspirin , antibiotic ) Subject already participate trial 3months Subject whole blood donation 2months , component blood donation 1months transfusion 1months currently . Smokers . ( , subject did'nt smoke 3months , participate trial )</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>